Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18535817 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL661089 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL1015665 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL1015667 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL5831542 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL20758481 | 1.00 | PPM1D (0.34) | PPM1D | |
| SCHEMBL25382185 | 0.89 | PPM1D (0.35) | PPM1D | |
| SCHEMBL660447 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711228 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711230 | 0.89 | PPM1D (0.38) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3356344-B1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LTD (GB) | 2022-11-16 | — | — | EP | disclosed |
| CN-108473464-B | Isoindolinone inhibitors of MDM2-P53 interaction with anti-cancer activity | 阿斯泰克斯治疗有限公司 | 2022-08-23 | — | — | CN | disclosed |
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2022-04-07 | — | — | US | disclosed |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | ASTEX THERAPEUTICS LIMITED (GB) | 2022-03-01 | — | — | US | disclosed |
| WO-2020260857-A1 | HYDROXAMATE COMPOUNDS AS ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | AdoRx Therapeutics Limited (GB) | 2020-12-30 | — | — | WO | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2019-02-21 | — | — | US | disclosed |
| EP-3356344-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | Astex Therapeutics Ltd (GB) | 2018-08-08 | — | — | EP | disclosed |
| EP-2125745-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI SA (FR) | 2017-02-22 | — | — | EP | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| EP-1358180-A2 | NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASES | F. Hoffmann-La Roche AG (CH) | 2003-11-05 | — | — | EP | disclosed |
| US-6531598-B1 | Naphthostyrils | HOFFMANN-LA ROCHE INC. | 2003-03-11 | — | — | US | disclosed |
| US-6504034-B2 | Cell antiproliferative agents; anticancer agents | HOFFMANN-LA ROCHE INC. | 2003-01-07 | — | — | US | disclosed |
| US-20020147343-A1 | Naphthostyrils | CHEN YI (US) | 2002-10-10 | — | — | US | disclosed |
| WO-2002059109-A2 | NAPHTHOSTYRIL DERIVATIVES AND THEIR USE AS INHIBITORS OF CYCLIN- DEPENDENT KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-01 | — | — | WO | disclosed |
| US-5808112-A | Preparation of cis-4-O-protected-2-cyclopentenol derivatives | HOECHST MARION ROUSSEL INC. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5728899-A | Preparation of cis-4-O-protected-2-cyclopentenol derivatives | HOECHST MARION ROUSSEL INC. (US) | 1998-03-17 | — | — | US | disclosed |
| EP-0817764-A1 | PREPARATION OF CIS-4-O-PROTECTED-2-CYCLOPENTENOL DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1998-01-14 | — | — | EP | disclosed |
| WO-1996031476-A1 | AROMATIC HYDROXYETHERS | RHONE-POULENC RORER LIMITED (GB) | 1996-10-10 | — | — | WO | disclosed |
| WO-1996030320-A1 | PREPARATION OF CIS-4-O-PROTECTED-2-CYCLOPENTENOL DERIVATIVES | HOECHST MARION ROUSSEL, INC. (US) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106287-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | PPM1D 371/4885 |
| US-20020147343-A1 | Naphthostyrils | CCNI, CDKL1, CDK2 | PPM1D 484/4885 |
| US-20190055215-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | PPM1D 371/4885 |
| US-11261171-B1 | Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity | TP53, MDM2, TP53BP1 | PPM1D 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.